MedTrace Logo

Cathflo Activase Pediatric Study

NCT00307580 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2014-04-09

No results posted yet for this study

Summary

This was a Phase IV, open-label, single-arm, multicenter trial that was to be conducted at \~60 sites in the United States. Approximately 300 pediatric subjects with dysfunctional CVADs (including catheters with valves, multiple lumens, umbilical catheters, and implanted ports) were to be treated with up to two serially instilled doses of Cathflo Activase.

Conditions

  • Dysfunctional Central Venous Access Devices (CVADS)

Interventions

DRUG

Cathflo Activase (Alteplase)

Sponsors & Collaborators

  • Genentech, Inc.

    lead INDUSTRY

Principal Investigators

  • Martha Blaney, PharmD · Genentech, Inc.

Study Design

Purpose
TREATMENT

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-04-30
Completion
2003-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00307580 on ClinicalTrials.gov